eIF

所有产品 eIF抑制剂(3)

目录号	产品描述	文献引用	实验数据
S7369	4EGI-1 4EGI-1是通过结合eIF4E，竞争性的作用于eIF4E/eIF4G相互作用的抑制剂，其K_D值为25 μM。	Mol Cell, 2019, 10.1016/j.molcel.2019.11.010 Brain, 2019, 142(1):176-192 J Exp Clin Cancer Res, 2019, 38(1):66	Hep3B and PC3 cells were treated with 50 μmol/L 4EGI-1 or 5 μmol/L ABT alone or their combination for 48 hours, and then the cell viability was examined by CCK-8 assay. p, phosphorylated; t, total; T, Thr; S, Ser; , P < 0.05; , P < 0.01; **, P < 0.001.
S7370	4E1RCat 4E1RCat 是一种eIF4E:eIF4G和eIF4E:4E-BP1相互作用的双重抑制剂,以IC50为3.2μM来抑制eIF4G 结合到eIF4E.	Int J Ophthalmol, 2020, 13(1):7-10 Sci Transl Med, 2019, 11(503) Acta Neuropathol Commun, 2018, 6(1):48	Immunoblot analysis of IRF7 in wild-type FL-pDCs pretreated with 50 µM 4E1Rcat (4E1R) or DMSO 6 h following stimulation with CpG ODN (1 µM) for 15 min.
S8181	SBI-0640756 SBI-0640756是靶向eIF4G1首创抑制剂，可破坏eIF4F复合体。

目录号

产品描述

文献引用

实验数据

S7369

4EGI-1是通过结合eIF4E，竞争性的作用于eIF4E/eIF4G相互作用的抑制剂，其K_D值为25 μM。

S7370

4E1RCat 是一种eIF4E:eIF4G和eIF4E:4E-BP1相互作用的双重抑制剂,以IC50为3.2μM来抑制eIF4G 结合到eIF4E.

S8181

SBI-0640756是靶向eIF4G1首创抑制剂，可破坏eIF4F复合体。

目录号	产品描述	文献引用	实验数据
S7369	4EGI-1 4EGI-1是通过结合eIF4E，竞争性的作用于eIF4E/eIF4G相互作用的抑制剂，其K_D值为25 μM。	Mol Cell,2019, 10.1016/j.molcel.2019.11.010 Brain,2019, 142(1):176-192 J Exp Clin Cancer Res,2019, 38(1):66	Hep3B and PC3 cells were treated with 50 μmol/L 4EGI-1 or 5 μmol/L ABT alone or their combination for 48 hours, and then the cell viability was examined by CCK-8 assay. p, phosphorylated; t, total; T, Thr; S, Ser; , P < 0.05; , P < 0.01; **, P < 0.001.
S7370	4E1RCat 4E1RCat 是一种eIF4E:eIF4G和eIF4E:4E-BP1相互作用的双重抑制剂,以IC50为3.2μM来抑制eIF4G 结合到eIF4E.	Int J Ophthalmol,2020, 13(1):7-10 Sci Transl Med,2019, 11(503) Acta Neuropathol Commun,2018, 6(1):48	Immunoblot analysis of IRF7 in wild-type FL-pDCs pretreated with 50 µM 4E1Rcat (4E1R) or DMSO 6 h following stimulation with CpG ODN (1 µM) for 15 min.
S8181	SBI-0640756 SBI-0640756是靶向eIF4G1首创抑制剂，可破坏eIF4F复合体。

目录号

产品描述

文献引用

实验数据

S7369